Current and historical daily PE Ratio for Biogen Inc (
STU:IDP
) from 1990 to Jun 20 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Biogen stock (STU:IDP) PE ratio as of Jun 20 2024 is 27.92.
More Details
Biogen Inc (STU:IDP) PE Ratio (TTM) Chart
Biogen Inc (STU:IDP) PE Ratio (TTM) Historical Data
View and export this data going back to 1990. Start your Free Trial
Total 1265
- 1
- 2
- 3
- 4
- 5
- 6
- 15
| Biogen PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-20 | 27.9 | 2024-04-17 | 24.7 |
| 2024-06-19 | 27.9 | 2024-04-16 | 25.0 |
| 2024-06-18 | 28.6 | 2024-04-15 | 25.3 |
| 2024-06-17 | 28.7 | 2024-04-12 | 25.4 |
| 2024-06-14 | 29.3 | 2024-04-11 | 25.8 |
| 2024-06-13 | 29.4 | 2024-04-10 | 25.4 |
| 2024-06-12 | 28.4 | 2024-04-09 | 26.0 |
| 2024-06-11 | 28.7 | 2024-04-08 | 25.6 |
| 2024-06-10 | 28.6 | 2024-04-05 | 25.7 |
| 2024-06-07 | 28.8 | 2024-04-04 | 25.8 |
| 2024-06-06 | 28.9 | 2024-04-03 | 26.1 |
| 2024-06-05 | 29.1 | 2024-04-02 | 27.1 |
| 2024-06-04 | 28.5 | 2024-03-28 | 26.9 |
| 2024-06-03 | 28.8 | 2024-03-27 | 26.9 |
| 2024-05-31 | 27.9 | 2024-03-26 | 26.7 |
| 2024-05-30 | 27.2 | 2024-03-25 | 27.0 |
| 2024-05-29 | 26.8 | 2024-03-22 | 27.2 |
| 2024-05-28 | 27.1 | 2024-03-21 | 27.4 |
| 2024-05-27 | 27.2 | 2024-03-20 | 27.1 |
| 2024-05-24 | 27.2 | 2024-03-19 | 27.3 |
| 2024-05-23 | 28.3 | 2024-03-18 | 27.3 |
| 2024-05-22 | 28.2 | 2024-03-15 | 27.3 |
| 2024-05-21 | 28.3 | 2024-03-14 | 28.1 |
| 2024-05-20 | 28.8 | 2024-03-13 | 28.0 |
| 2024-05-17 | 28.7 | 2024-03-12 | 28.2 |
| 2024-05-16 | 28.8 | 2024-03-11 | 28.5 |
| 2024-05-15 | 28.3 | 2024-03-08 | 27.8 |
| 2024-05-14 | 28.3 | 2024-03-07 | 27.0 |
| 2024-05-13 | 28.2 | 2024-03-06 | 27.0 |
| 2024-05-10 | 28.1 | 2024-03-05 | 27.2 |
| 2024-05-09 | 27.6 | 2024-03-04 | 27.5 |
| 2024-05-08 | 27.9 | 2024-03-01 | 27.2 |
| 2024-05-07 | 27.7 | 2024-02-29 | 27.6 |
| 2024-05-06 | 27.9 | 2024-02-28 | 27.9 |
| 2024-05-03 | 27.1 | 2024-02-27 | 27.9 |
| 2024-05-02 | 27.2 | 2024-02-26 | 27.8 |
| 2024-04-30 | 27.4 | 2024-02-23 | 28.0 |
| 2024-04-29 | 27.1 | 2024-02-22 | 27.8 |
| 2024-04-26 | 26.4 | 2024-02-21 | 27.6 |
| 2024-04-25 | 25.3 | 2024-02-20 | 27.6 |
| 2024-04-24 | 25.4 | 2024-02-19 | 27.6 |
| 2024-04-23 | 24.6 | 2024-02-16 | 27.6 |
| 2024-04-22 | 24.6 | 2024-02-15 | 28.1 |
| 2024-04-19 | 24.6 | 2024-02-14 | 28.5 |
| 2024-04-18 | 24.3 | 2024-02-13 | 28.8 |
Biogen Inc (STU:IDP) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Biogen Inc
NAICS : 325412
SIC : 2834
ISIN : US09062X1037
Description
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers